Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 299

1.

A plethora of manifestations following a Mycoplasma pneumoniae infection: a case report.

Matthys I, Borsboom D, Steyaert S, Vervloet D, Cornelis K, Vanderstraeten E, Kindt S, Dewint P, Lambrecht V, Sinnaeve P, Van Steenkiste C.

Acta Clin Belg. 2019 Feb 15:1-6. doi: 10.1080/17843286.2019.1578029. [Epub ahead of print]

PMID:
30767713
2.

The impact of drop-out in cardiac rehabilitation on outcome among coronary artery disease patients.

Pardaens S, Willems AM, Clays E, Baert A, Vanderheyden M, Verstreken S, Du Bois I, Vervloet D, De Sutter J.

Eur J Prev Cardiol. 2017 Sep;24(14):1490-1497. doi: 10.1177/2047487317724574. Epub 2017 Jul 31.

PMID:
28758419
3.

Aggressive extensive cardiac mass in an HIV-1-infected patient: should we go for comfort therapy?

Vervloet DM, De Pauw M, Demulier L, Vercammen J, Terryn W, Steel E, Vandekerckhove L.

Acta Clin Belg. 2017 Jun;72(3):198-200. doi: 10.1080/17843286.2016.1175703. Epub 2016 Jun 14.

PMID:
27355914
4.

Nuclear cardiac imaging for the diagnosis and management of heart failure: what can be learned from recent guidelines?

Vervloet DM, DE Sutter J.

Q J Nucl Med Mol Imaging. 2016 Jan 20. [Epub ahead of print]

PMID:
26788807
5.

Granulomatosis with polyangiitis (Wegener's) hidden in the aortic valve.

Vervloet DM, De Backer T, Van Dorpe J.

Int J Cardiovasc Imaging. 2016 May;32(5):753-5. doi: 10.1007/s10554-016-0835-y. Epub 2016 Jan 11. No abstract available.

PMID:
26754429
6.

Diagnostic accuracy of a novel method for detection of acute transmural myocardial ischemia based upon a self-applicable 3-lead configuration.

El Haddad M, Vervloet D, Taeymans Y, De Buyzere M, Bové T, Stroobandt R, Duytschaever M, Malmivuo J, Gheeraert P.

J Electrocardiol. 2016 Mar-Apr;49(2):192-201. doi: 10.1016/j.jelectrocard.2015.11.007. Epub 2015 Nov 23.

PMID:
26702768
7.

Adherence: the goal to control asthma.

Boulet LP, Vervloet D, Magar Y, Foster JM.

Clin Chest Med. 2012 Sep;33(3):405-17. doi: 10.1016/j.ccm.2012.06.002. Epub 2012 Aug 2. Review.

PMID:
22929091
8.

Variable content of Fel d 1 variants in house dust and cat extracts may have an impact on allergen measurement.

Bienboire-Frosini C, Lebrun R, Vervloet D, Pageat P, Ronin C.

J Investig Allergol Clin Immunol. 2012;22(4):270-9.

9.

Asthma control assessed in the EGEA epidemiological survey and health-related quality of life.

Siroux V, Boudier A, Bousquet J, Vignoud L, Gormand F, Just J, Le Moual N, Leynaert B, Nadif R, Pison C, Scheinmann P, Vervloet D, Anto JM, Kauffmann F, Pin I.

Respir Med. 2012 Jun;106(6):820-8. doi: 10.1016/j.rmed.2012.01.009. Epub 2012 Feb 23.

10.

Immunological differences in the global release of the major cat allergen Fel d 1 are influenced by sex and behaviour.

Bienboire-Frosini C, Cozzi A, Lafont-Lecuelle C, Vervloet D, Ronin C, Pageat P.

Vet J. 2012 Jul;193(1):162-7. doi: 10.1016/j.tvjl.2011.09.031. Epub 2011 Nov 1.

PMID:
22044714
11.

Air pollution and asthma control in the Epidemiological study on the Genetics and Environment of Asthma.

Jacquemin B, Kauffmann F, Pin I, Le Moual N, Bousquet J, Gormand F, Just J, Nadif R, Pison C, Vervloet D, Künzli N, Siroux V; Epidemiological study on the Genetics and Environment of Asthma (EGEA).

J Epidemiol Community Health. 2012 Sep;66(9):796-802. Epub 2011 Jun 20.

12.

Environmental home inspection services in Western Europe.

Charpin D, Baden R, Bex V, Bladt S, Charpin-Kadouch C, Keimeul C, da Mata P, de Blay F, Kuske M, Le Moullec Y, Nicolas A, Ott M, Marc R, Speyer C, Vervloet D, Squinazi F.

Environ Health Prev Med. 2011 Mar;16(2):73-9. doi: 10.1007/s12199-010-0171-0. Epub 2010 Aug 14. Review.

13.

Differences in allergen-induced T cell activation between allergic asthma and rhinitis: Role of CD28, ICOS and CTLA-4.

Botturi K, Lacoeuille Y, Cavaillès A, Vervloet D, Magnan A.

Respir Res. 2011 Feb 28;12:25. doi: 10.1186/1465-9921-12-25.

14.

Insights into severe asthma control as assessed by guidelines, pulmonologist, patient, and partner.

Molimard M, Vervloet D, Le Gros V, Bourdeix I, Ponthieux A.

J Asthma. 2010 Oct;47(8):853-9. doi: 10.3109/02770903.2010.491139.

PMID:
20854028
15.

Histamine induces Th2 activation through the histamine receptor 1 in house dust mite rhinitic but not asthmatic patients.

Botturi K, Lacoeuille Y, Vervloet D, Magnan A.

Clin Exp Allergy. 2010 May;40(5):755-62. doi: 10.1111/j.1365-2222.2010.03457.x. Epub 2010 Feb 25.

PMID:
20184607
16.

Distribution of core fragments from the major cat allergen Fel d 1 is maintained among the main anatomical sites of production.

Bienboire-Frosini C, Lebrun R, Vervloet D, Pageat P, Ronin C.

Int Arch Allergy Immunol. 2010;152(3):197-206. doi: 10.1159/000283024. Epub 2010 Feb 10.

PMID:
20145408
17.

17q21 variants modify the association between early respiratory infections and asthma.

Smit LA, Bouzigon E, Pin I, Siroux V, Monier F, Aschard H, Bousquet J, Gormand F, Just J, Le Moual N, Nadif R, Scheinmann P, Vervloet D, Lathrop M, Demenais F, Kauffmann F; EGEA Cooperative Group.

Eur Respir J. 2010 Jul;36(1):57-64. doi: 10.1183/09031936.00154509. Epub 2009 Dec 23.

18.

Phenotypic determinants of uncontrolled asthma.

Siroux V, Boudier A, Bousquet J, Bresson JL, Cracowski JL, Ferran J, Gormand F, Just J, Le Moual N, Morange S, Nadif R, Oryszczyn MP, Pison C, Scheinmann P, Varraso R, Vervloet D, Pin I, Kauffmann F; Epidemiological Study on the Genetics and Environment of Asthma.

J Allergy Clin Immunol. 2009 Oct;124(4):681-7.e3. doi: 10.1016/j.jaci.2009.06.010. Epub 2009 Aug 8.

PMID:
19665764
19.
20.

Allergen-specific immunotherapy in allergic rhinitis and asthma. Mechanisms and proof of efficacy.

Pipet A, Botturi K, Pinot D, Vervloet D, Magnan A.

Respir Med. 2009 Jun;103(6):800-12. doi: 10.1016/j.rmed.2009.01.008. Epub 2009 Feb 12. Review.

21.

Effect of 17q21 variants and smoking exposure in early-onset asthma.

Bouzigon E, Corda E, Aschard H, Dizier MH, Boland A, Bousquet J, Chateigner N, Gormand F, Just J, Le Moual N, Scheinmann P, Siroux V, Vervloet D, Zelenika D, Pin I, Kauffmann F, Lathrop M, Demenais F.

N Engl J Med. 2008 Nov 6;359(19):1985-94. doi: 10.1056/NEJMoa0806604. Epub 2008 Oct 15.

22.

T-cell activation during exacerbations: a longitudinal study in refractory asthma.

Mamessier E, Nieves A, Lorec AM, Dupuy P, Pinot D, Pinet C, Vervloet D, Magnan A.

Allergy. 2008 Sep;63(9):1202-10. doi: 10.1111/j.1398-9995.2008.01687.x.

PMID:
18699937
23.

Asthma and allergy: short texts and recommendations of the expert conference of the French Speaking Pneumology Society (SPLF), in partnership with the French Society of Allergology and Clinical Immunology (SFAIC), the French Society of Occupational Medicine (SFMT) and the "Asthma-Allergy" association.

Tillie-Leblond I, Magnan A, Pauli G, Vervloet D, Wallaert B, Didier A, Ameille J, Godard P; French Speaking Pneumology Society; French Society of Allergology and Clinical Immunology; French Society of Occupational Medicine; Asthma-Allergy association.

Respir Med. 2008 Oct;102(10):1483-93. doi: 10.1016/j.rmed.2008.03.002. Epub 2008 Jul 21.

24.

What is an Allergist?: Reconciled Document Incorporating Member Society Comments, September 3, 2007.

Del Giacco S, Rosenwasser LJ, Crisci CD, Frew AJ, Kaliner MA, Lee BW, Guanghui L, Maspero J, Moon HB, Takemasa N, Potter PC, Singh AB, Valovirta E, Vervloet D, Warner JO, Henley K; position statement of the WAO Specialty and Training Council:.

World Allergy Organ J. 2008 Jan;1(1):19-20. doi: 10.1097/wox.0b013e3181651679. No abstract available.

25.

[Exacerbation in asthma: definitions and immunopathology].

Cavaillès A, Pinot D, Nieves A, Botturi K, Lorec AM, Vervloet D, Lara MT, Magnan A.

Presse Med. 2008 Jan;37(1 Pt 2):136-42. Epub 2007 Dec 11. Review. French.

PMID:
18065189
26.

[Does asthma represent a risk factor for anaphylaxis?].

Vervloet D, Rancé F, Birnbaum J, Clément O.

Rev Mal Respir. 2007 Oct;24(8 Pt 3):7S27-33. French. No abstract available.

PMID:
18033200
27.

Evidence for linkage of a new region (11p14) to eczema and allergic diseases.

Guilloud-Bataille M, Bouzigon E, Annesi-Maesano I, Bousquet J, Charpin D, Gormand F, Hochez J, Just J, Lemainque A, Le Moual N, Matran R, Neukirch F, Oryszczyn MP, Paty E, Pin I, Vervloet D, Kauffmann F, Lathrop M, Demenais F, Dizier MH.

Hum Genet. 2008 Jan;122(6):605-14. Epub 2007 Oct 18.

28.

T cells and allergens relationships: are they that specific?

Botturi K, Vervloet D, Magnan A.

Clin Exp Allergy. 2007 Aug;37(8):1121-3. Review. No abstract available.

PMID:
17651139
29.

[Therapeutic education in the asthmatic patient].

Vervloet D.

Rev Mal Respir. 2002 Feb;19(1):29-32. French. No abstract available.

PMID:
17546809
30.

[Environmental factors for asthma severity and allergy: results from the EGEA study].

Siroux V, Oryszczyn MP, Varraso R, Le Moual N, Bousquet J, Charpin D, Gormand F, Kennedy S, Maccario J, Pison C, Rage E, Scheinmann P, Vervloet D, Pin I, Kauffmann F.

Rev Mal Respir. 2007 May;24(5):599-608. French.

31.

T-cell activation in occupational asthma and rhinitis.

Mamessier E, Milhe F, Guillot C, Birnbaum J, Dupuy P, Lorec AM, Vervloet D, Magnan A.

Allergy. 2007 Feb;62(2):162-9.

PMID:
17298425
32.

[Education, is it the answer?].

Lamouroux A, Vervloet D.

Rev Mal Respir. 2006 Sep;23(4 Pt 2):10S37-10S40. Review. French. No abstract available.

PMID:
17127961
33.

Safety and efficacy of Juniperus ashei sublingual-swallow ultra-rush pollen immunotherapy in cypress rhinoconjunctivitis. A double-blind, placebo-controlled study.

Vervloet D, Birnbaum J, Laurent P, Hugues B, Fardeau MF, Massabie-Bouchat YP, Aferiat-Derome A, André C.

Int Arch Allergy Immunol. 2007;142(3):239-46. Epub 2006 Nov 15.

PMID:
17114889
34.

Ultra-rush venom immunotherapy induces differential T cell activation and regulatory patterns according to the severity of allergy.

Mamessier E, Birnbaum J, Dupuy P, Vervloet D, Magnan A.

Clin Exp Allergy. 2006 Jun;36(6):704-13.

PMID:
16776670
35.

Do patients with skin allergies have higher levels of anxiety than patients with allergic respiratory diseases? Results of a large-scale cross-sectional study in a French population.

Annesi-Maesano I, Beyer A, Marmouz F, Mathelier-Fusade P, Vervloet D, Bauchau V.

Br J Dermatol. 2006 Jun;154(6):1128-36.

PMID:
16704645
36.

[Pathophysiological mechanisms of asthma and atopy: old and new concepts].

Magnan A, Vervloet D.

Bull Acad Natl Med. 2005 Oct;189(7):1451-9; discussion 1460. Review. French.

PMID:
16669144
37.

Diesel exhaust particles enhance T-cell activation in severe asthmatics.

Mamessier E, Nieves A, Vervloet D, Magnan A.

Allergy. 2006 May;61(5):581-8.

PMID:
16629788
38.

Concurrent allergic diseases: a cross-sectional study in a French population.

Annesi-Maesano I, Beyer A, Marmouz F, Mathelier-Fusade P, Vervloet D, Bauchau V.

Allergy. 2006 Mar;61(3):390-1. No abstract available.

PMID:
16436152
39.

Variation of T-cell activation in allergic subjects during natural pollen exposure.

Koscher V, Milhe F, El Biaze M, Vervloet D, Magnan A.

Allergy. 2006 Jan;61(1):35-42.

PMID:
16364154
40.

[T regulatory lymphocytes, atopy and asthma: a new concept in three dimensions].

Mamessier E, Botturi K, Vervloet D, Magnan A.

Rev Mal Respir. 2005 Apr;22(2 Pt 1):305-11. Review. French.

PMID:
16092167
41.

[Economic burden of COPD: the SCOPE study].

Fournier M, Tonnel AB, Housset B, Huchon G, Godard P, Vervloet D, Huas D, Durand-Zaleski I, Chanal I, Pribil C; Groupe SCOPE.

Rev Mal Respir. 2005 Apr;22(2 Pt 1):247-55. French.

PMID:
16092163
42.

[The asthma schools].

Vervloet D, Rolland C; l'Association Asthme & Allergies.

Rev Mal Respir. 2005 Apr;22(2 Pt 3):4S16-8. French. No abstract available.

PMID:
15976644
43.

Dog factor differences in Can f 1 allergen production.

Ramadour M, Guetat M, Guetat J, El Biaze M, Magnan A, Vervloet D.

Allergy. 2005 Aug;60(8):1060-4.

PMID:
15969688
44.

[Compliance, therapeutic observance and therapeutic adherence: what do we speak about?].

Lamouroux A, Magnan A, Vervloet D.

Rev Mal Respir. 2005 Feb;22(1 Pt 1):31-4. French. No abstract available.

PMID:
15968755
45.

Twenty five year mortality and air pollution: results from the French PAARC survey.

Filleul L, Rondeau V, Vandentorren S, Le Moual N, Cantagrel A, Annesi-Maesano I, Charpin D, Declercq C, Neukirch F, Paris C, Vervloet D, Brochard P, Tessier JF, Kauffmann F, Baldi I.

Occup Environ Med. 2005 Jul;62(7):453-60.

46.

Assessment of a therapeutic education programme for asthma patients: "un souffle nouveau".

Magar Y, Vervloet D, Steenhouwer F, Smaga S, Mechin H, Rocca Serra JP, Marchand C, d'Ivernois JF.

Patient Educ Couns. 2005 Jul;58(1):41-6.

PMID:
15950835
47.

[Epidemiology of seasonal spring-time allergic rhinitis in adults in France].

Klossek JM, Gohler C, Vervloet D, Deslandes B, Dufour X, Neukirch F.

Presse Med. 2005 Mar 12;34(5):348-52. French.

PMID:
15859567
48.

Phenotypes of asthma revisited upon the presence of atopy.

Nieves A, Magnan A, Boniface S, Proudhon H, Lanteaume A, Romanet S, Vervloet D, Godard P; ARIA.

Respir Med. 2005 Mar;99(3):347-54.

49.

Genome screen in the French EGEA study: detection of linked regions shared or not shared by allergic rhinitis and asthma.

Dizier MH, Bouzigon E, Guilloud-Bataille M, Bétard C, Bousquet J, Charpin D, Gormand F, Hochez J, Just J, Lemainque A, Le Moual N, Matran R, Neukirch F, Oryszczyn MP, Paty E, Pin I, Vervloet D, Kauffmann F, Lathrop M, Demenais F, Annesi-Maesano I.

Genes Immun. 2005 Mar;6(2):95-102.

PMID:
15674395
50.

[2000 classification of idiopathic interstitial lung diseases].

Boniface S, Gaubert JY, Chetaille B, Fraticelli A, Retornaz F, Astoul P, Vervloet D, Magnan A, Reynaud-Gaubert M.

Rev Med Interne. 2004 Dec;25(12):891-905. Review. French.

PMID:
15582169

Supplemental Content

Loading ...
Support Center